TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05090150

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home delivery of ART
Description: Home ART refill and monitoring, adherence support

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home delivery of ART
Description: Home ART refill and monitoring, adherence support

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smart Lockers (Pele boxes)
Description: Decentralized ART refills and monitoring, adherence support

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smart Lockers (Pele boxes)
Description: Decentralized ART refills and monitoring, adherence support

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best clinic practices + conditional lottery incentives
Description: Conditional lottery incentives Welcome back service (friendly providers, SMS, adherence support) Fast-track ART

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best clinic practices + conditional lottery incentives
Description: Conditional lottery incentives Welcome back service (friendly providers, SMS, adherence support) Fast-track ART

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best clinic practices + conditional lottery incentives
Description: Conditional lottery incentives Welcome back service (friendly providers, SMS, adherence support) Fast-track ART

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best clinic practices
Description: Continue with best clinic practices

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best clinic practices
Description: Continue with best clinic practices
Study: NCT06171880

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JLP-1901
Description: administration of JLP-1901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JLP-1901
Description: administration of JLP-1901

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JC-001(active comparator)
Description: administration of JC-001(tenofovir)
Study: NCT06223490

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryolipolysis
Description: To investigate the Effect of Cryolipolysis On insulin resistance and In adult type 2 female patients.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryolipolysis
Description: To investigate the Effect of Cryolipolysis On insulin resistance and In adult type 2 female patients.
Study: NCT06781060

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy Standard Treatment with TENS machine therapy
Description: The control group in which Standard Physiotherapy + TENS therapy will be provided to the participants.
Study: NCT06781814

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotic strips with different strain formulas, take two strips daily. Storage method: Keep away from light, seal tightly, and store in a cool, dry place.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotic strips with different strain formulas, take two strips daily. Storage method: Keep away from light, seal tightly, and store in a cool, dry place.
Study: NCT05529576

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 fatty acid
Description: Omega-3 fatty acids complementation according to the patient's CRP level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acid
Description: Omega-3 fatty acids complementation according to the patient's CRP level
Study: NCT06780124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE63-0302 or placebo
Description: The participants will receive ZE63-0302 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE63-0302 or placebo
Description: The participants will receive ZE63-0302 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE63-0302 or placebo
Description: The participants will receive ZE63-0302 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE63-0302 or placebo
Description: The participants will receive ZE63-0302 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE63-0302 or placebo
Description: The participants will receive ZE63-0302 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE63-0302 or placebo
Description: The participants will receive ZE63-0302 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE63-0302 or placebo
Description: The participants will receive ZE63-0302 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE63-0302 or placebo
Description: The participants will receive ZE63-0302 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE63-0302 or placebo
Description: The participants will receive ZE63-0302 or placebo
Study: NCT06782243

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-Intensity Statins
Description: Participants will be administered statins based on moderate intensity. This group will receive oral tablets once daily for 3 months. The intervention includes Atorvastatin 20 mg and rosuvastatin 10 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High-Intensity Statins
Description: Participants will be administered statins based on high intensity. This group will receive oral tablets once daily for 3 months. The intervention includes Atorvastatin 40 mg and rosuvastatin 20 mg.
Study: NCT06780137

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-6070
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-6070
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-6070
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-6070
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ifinatamab Deruxtecan (I-DXd)
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ifinatamab Deruxtecan (I-DXd)
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ifinatamab Deruxtecan (I-DXd)
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ifinatamab Deruxtecan (I-DXd)
Description: IV infusion
Study: NCT06780488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real Visual-Vestibuar Rehabilitation
Description: The Real Visual-Vestibular Rehabilitation protocol will consist of specific exercises aimed at stimulating the visuo-vestibular function within immersive virtual reality environments replicating daily life situations. Patients will perform exercises in two types of contexts. In all exercises, patients will be free to move within a room large enough to complete the tasks. Walking during the exercises can also be performed with assistive devices, to make the context as close as possible to the patient's daily life. During the exercises, patients will be supervised by a physiotherapist specialized in neurological and vestibular rehabilitation.The protocol will last 20 minutes, with 10 minutes dedicated to each exercise.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Rehabilitation
Description: The Sham Vestibular Rehabilitation protocol will involve the use of the same immersive virtual reality contexts and will aim to achieve the same objectives as the Real Visual-Vestibular Rehabilitation protocol, but without the unexpected stimuli. In both exercises, patients will be free to move within a room large enough to complete the tasks. Walking during the session can also be performed with assistive devices, to make the context as close as possible to the patient's daily life. During the exercises, patients will be supervised by a physiotherapist specialized in neurological and vestibular rehabilitation. The protocol will last 20 minutes, with 10 minutes dedicated to each exercise.
Study: NCT06780683

Intervention type: DRUG
Intervention: Upadacitinib
Description: Induction Therapy: The dose of upadacitinib for induction therapy is 45mg once daily for a duration of 8 weeks (for ulcerative colitis) or 12 weeks (for Crohn's disease).~Maintenance Therapy: The dose of upadacitinib for maintenance therapy is 15mg once daily; for patients with refractory, severe, or extensive disease, a maintenance dose of 30mg once daily may be considered.

Intervention type: DRUG
Intervention: Upadacitinib
Description: Induction Therapy: The dose of upadacitinib for induction therapy is 45mg once daily for a duration of 8 weeks (for ulcerative colitis) or 12 weeks (for Crohn's disease).~Maintenance Therapy: The dose of upadacitinib for maintenance therapy is 15mg once daily; for patients with refractory, severe, or extensive disease, a maintenance dose of 30mg once daily may be considered.
Study: NCT06780345

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mechanically ventilated neonates will receive the usual protocol of sepsis and a placebo without vitamin C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Mechanically ventilated neonates will receive the usual protocol of sepsis plus vitamin C with a loading dose of 0.5 gm /kg and a maintenance dose of 0.5 gm /kg/hour adjusted for six hours for 7-10 days.
Study: NCT04535414

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellvizio (Registered trademark) Real-Time In Vivo Cellular Imaging Platform with Confocal Miniprobes
Description: Participants of both study arms will undergo confocal endomicroscopy of the gastric mucosa until sufficient data for statistically accurate and reliable application of machine learning (i.e., computer models), currently believed to total the first 50 enrolled participants.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cellvizio (Registered trademark) Real-Time In Vivo Cellular Imaging Platform with Confocal Miniprobes
Description: Participants of both study arms will undergo confocal endomicroscopy of the gastric mucosa until sufficient data for statistically accurate and reliable application of machine learning (i.e., computer models), currently believed to total the first 50 enrolled participants.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus Graphics Interchange Format (GIF) 190 endoscope
Description: Participants will undergo white light endoscopy. The mucosa of the stomach may be thoroughly washed before examination, as medically indicated, and inspection will include repeated inflation and deflation to check distensibility and any abnormal appearing areas will additionally be biopsied. Nontargeted biopsies will be obtained as indicated per the assigned Arm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Olympus Graphics Interchange Format (GIF) 190 endoscope
Description: Participants will undergo white light endoscopy. The mucosa of the stomach may be thoroughly washed before examination, as medically indicated, and inspection will include repeated inflation and deflation to check distensibility and any abnormal appearing areas will additionally be biopsied. Nontargeted biopsies will be obtained as indicated per the assigned Arm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric mucosal biopsy
Description: As clinically indicated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric mucosal biopsy
Description: As clinically indicated.
Study: NCT05929846

Intervention type: OTHER
Intervention: Back to Living Well Program
Description: The Back to Living Well program (BLW), a sustainable community-based program for persons with persistent mild to moderate LBP. The goal of the intervention is to provide an opportunity for community dwelling persons with persistent mild to moderate LBP to learn how to safely engage in exercise and become active self-managers. The 12-week program will engage participants in weekly exercise sessions, education and self management sessions, and encourage independent exercise at least 1x per week. All participants will be encouraged to complete an action plan and watch online education videos weekly.

Intervention type: OTHER
Intervention: Back to Living Well Program
Description: The Back to Living Well program (BLW), a sustainable community-based program for persons with persistent mild to moderate LBP. The goal of the intervention is to provide an opportunity for community dwelling persons with persistent mild to moderate LBP to learn how to safely engage in exercise and become active self-managers. The 12-week program will engage participants in weekly exercise sessions, education and self management sessions, and encourage independent exercise at least 1x per week. All participants will be encouraged to complete an action plan and watch online education videos weekly.
Study: NCT05665595

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Vibostolimab
Description: Co-formulation of pembrolizumab 200 mg/20 mL vial and vibostolimab 200 mg administered as IV infusion for up to 17 administrations

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab 25 mg/mL administered as IV infusion for up to 17 administrations
Study: NCT06398457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darzalex Faspro (Daratumumab and hyaluronidase-fihj)
Description: Darzalex Faspro will be administered weekly as a subcutaneous injection on Days -42, -35, -28 and -21 (+/- 1 day) for a total of four doses at 1800 mg each.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JH-DSA Semi-Quant Screen and Response Score
Description: Serum based semi-quantifiable investigational testing regimen used to screen for high DSA level or assess response to desensitization. It is based on results from cross-matched flow cytometric assessment cellular-based and solid phase immunoassays (SPI) that estimates antibody level.
Study: NCT04834362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analog Insulin
Description: For a patient who is known to have diabetes but were not getting insulin previously (or previous insulin dosage is not known), insulin therapy will be started at a total daily dose of 0.3-0.4 units/kg/day for an admission BG between 10-15 mmol/L or 0.5-0.6 units/kg/day for a BG \>15 mmol/L. In previously insulin treated patients, ongoing total daily dose of insulin will be started. If there is history of poor glycemic control with ongoing insulin dose, then 10-20% increase of daily dose of insulin will be considered.~For a patient who is not known to have diabetes, insulin therapy will be started if admission BG is \>10 mmol/L in two or more occasions. A total daily dose of 0.3-0.4 units/kg/day will be started if admission BG is 10-15 mmol/L and 0.5-0.6 units/kg/day for a BG \>15 mmol/L.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human insulin
Description: Patients treated with human insulin regimen will receive 50% of total daily dose as NPH insulin at around 6 am and 6 pm, while the rest 50% regular human insulin three times a day in 3 equally divided doses at around 6 am, 12 pm and 6 pm.
Study: NCT05733923

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Escavation
Description: Patients will receive an operative procedure to remove dental caries by traditional excavation using Carbide burs on a micromotor handpiece at low speed with air and water cooling.~- Group 6: 15 carious teeth will be excavated chemo-mechanically using Selecti-solve.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excavation with Sodium Hypochlorite Gel 2.5%.
Description: Patients will receive an operative procedure to remove dental caries by traditional excavation using Carbide burs on a micromotor handpiece at low speed with air and water cooling. In addition, teeth will be excavated chemo-mechanically using Sodium Hypochlorite Gel 2.5%.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excavation with Papacarie Duo
Description: Patients will receive an operative procedure to remove dental caries by traditional excavation using Carbide burs on a micromotor handpiece at low speed with air and water cooling. In addition, teeth will be excavated chemo-mechanically using a Papacarie Duo.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excavation with Brix3000
Description: Patients will receive an operative procedure to remove dental caries by traditional excavation using Carbide burs on a micromotor handpiece at low speed with air and water cooling. In addition, teeth will be excavated chemo-mechanically using a Brix3000.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excavation with Selecti-solve
Description: Patients will receive an operative procedure to remove dental caries by traditional excavation using Carbide burs on a micromotor handpiece at low speed with air and water cooling. In addition, teeth will be excavated chemo-mechanically using a Selecti-solve.
Study: NCT05280535

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cue Reactivity Task
Description: In the cue-reactivity task, participants will be exposed to either a combustible cigarette or e-cigarette cue (within-subjects randomized order across laboratory sessions) and a neutral water bottle cue. Participants will report their craving for cigarettes and e-cigarettes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Visual Dot Probe
Description: In the computerized visual dot probe task, participants will view a series of substance (cigarette or e-cigarette by trial block) versus neutral (water bottle) image trials and then respond to a subsequent image presented behind either the neutral or substance image. Order of block presentation within the task is randomized within-subjects across study sessions (i.e., cigarette OR e-cigarette block first).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice Task
Description: In the choice task, participants will choose between smoking their usual brand cigarette or their own e-cigarette over ten sequential ad-libbed trials.
Study: NCT05360758

Intervention type: OTHER
Intervention: Evaluation of response to treatment with response-tailored Ibrutinib in patients with chronic lymphocytic leukemia
Description: Evaluation of response to treatment with response-tailored Ibrutinib in patients with chronic lymphocytic leukemia using laboratory tests, abdominal ultrasound, general condition of the patient and bone marrow
Study: NCT04846205

Intervention type: DIAGNOSTIC_TEST
Intervention: systematic etiological
Description: Theses following tests are made as usual practice :~* Ventilator polygraphy, or polysomnography between 1 month and 1 year after cryptogenic ischemic stroke.~* Transoesophageal ultrasound
Study: NCT04607915

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention for TECC Model
Description: The Care Coordinator (CC) will provide brief coaching sessions (15 to 20 minutes) to each participant once per week for 8 weeks. Participants can identify topics for discussion and the CC and participant can decide if a video session via WebEx is required versus a phone call. Also, participants will be given peer support and will be indirectly monitored by a virtual care team of experts.
Study: NCT04569708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auditory stimulation
Description: Quiet auditory stimulation timed with sleep physiology
Study: NCT04822753

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Platelet Rich Plasma injection to the lumbar facet joint
Description: Using standard fluoroscopic view, place a needle at the target facet joint. Inject about 1ml of study injectate.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma injection to the lumbar facet joint
Description: Using standard fluoroscopic view, place a needle at the target facet joint. Inject about 1ml of study injectate.
Study: NCT06345209

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus-coated Coronary Balloon Dilatation Catheter
Description: During PCI, percutaneous transluminal coronary angioplasty is performed on the target lesion using the Sirolimus-coated Coronary Balloon Dilatation Catheter in the test group, subsequently completing the remaining procedure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-coated Coronary Balloon Dilatation Catheter
Description: During PCI, percutaneous transluminal coronary angioplasty is performed on the target lesion using the Drug-coated Coronary Balloon Dilatation Catheter in the test group, subsequently completing the remaining procedure
Study: NCT04917380

Intervention type: OTHER
Description: Retrospective clinical study，no intervention

Intervention type: OTHER
Description: Retrospective clinical study，no intervention
Study: NCT06171880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JC-001(active comparator)
Description: administration of JC-001(tenofovir)
Study: NCT06314191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: blood sampling with analyses

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blood sampling
Description: blood sampling with analyses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: knee radiography
Description: radiography of both knees in Schuss

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: knee radiography
Description: radiography of both knees in Schuss
Study: NCT05290103

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Game intervention
Description: Game intervention consists of 15-30 minutes digital health game playing at school and 2 weeks free usage of the digital health game during free time. In addition, after the 2 weeks period of game playing, 30-minute debriefing sessions with a research are held.~The digital health game includes visualized elements with sound effects that aim at increasing understanding about the consequences of tobacco product use and supporting refusal skills. The health game includes different mini-games and also textual information.~The debriefing sessions with a researcher include small group and group discussions about the themes presented in the game. A researcher leads and teachers facilitate the discussions. The debriefing sessions aim to connect the game experience with daily life situations.
Study: NCT05616182

Intervention type: OTHER
Intervention: LARS ligament and bone prosthesis replacement was performed
Description: To report the postoperative complications and limb function of patients who underwent LARS ligament and bone prosthesis replacement in Henan Cancer Hospital.
Study: NCT05132738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ripretinib treatment
Description: Ripretinib: 4-week (28-day) cycle of oral administration of 150 mg q.d. For patients who completed up to 6 consecutive treatment cycles in a the clinical investigator decided whether to perform the operation or not, the specific time and other matters.~The above medications can be adjusted according to the adverse reactions of subjects according to the protocol at the investigator's discretion. Subjects will continue treatment until disease progression, intolerable toxicity, withdrawal of informed consent, or discontinuation of treatment as judged by the investigator, and the investigator will decide whether to perform early surgery or subsequent treatment regimen.